Literature DB >> 8545113

Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element.

M Stadler1, M K Chelbi-Alix, M H Koken, L Venturini, C Lee, A Saïb, F Quignon, L Pelicano, M C Guillemin, C Schindler.   

Abstract

PML is a nuclear matrix protein with growth suppressing properties, whose expression is deregulated during oncogenesis. Moreover, in the t(15;17) translocation of acute promyelocytic leukaemia (APL), PML fusion to the retinoic acid receptor alpha (RAR alpha) is the likely molecular basis of leukaemogenesis. Here we show that interferons (IFNs) alpha, beta, and gamma upregulate PML mRNA expression. Analysis of 5' genomic sequences of the PML gene revealed an IFN-alpha/-beta stimulated response element (ISRE) and an IFN-gamma activation site (GAS) in the untranslated first exon. Binding of IFN signal transducers and activators of transcription (STATs) was demonstrated to be weak for the PML GAS, but strong for the PML ISRE which also seemed to contribute substantially to the IFN-gamma response. Thus, PML is a primary target gene of IFNs and would appear as a suitable candidate for mediating some of their antiproliferative effects. Abnormalities of PML structure, localisation or expression in human malignancy, constitute examples of how an IFN target gene may be altered in oncogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8545113

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  121 in total

1.  Efficient activation of viral genomes by levels of herpes simplex virus ICP0 insufficient to affect cellular gene expression or cell survival.

Authors:  W E Hobbs; D E Brough; I Kovesdi; N A DeLuca
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption.

Authors:  S Müller; A Dejean
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Sp100 interacts with ETS-1 and stimulates its transcriptional activity.

Authors:  Christine Wasylyk; Sophie E Schlumberger; Paola Criqui-Filipe; Bohdan Wasylyk
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

4.  PML is induced by oncogenic ras and promotes premature senescence.

Authors:  G Ferbeyre; E de Stanchina; E Querido; N Baptiste; C Prives; S W Lowe
Journal:  Genes Dev       Date:  2000-08-15       Impact factor: 11.361

5.  Lytic but not latent replication of epstein-barr virus is associated with PML and induces sequential release of nuclear domain 10 proteins.

Authors:  P Bell; P M Lieberman; G G Maul
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Acetylation is indispensable for p53 antiviral activity.

Authors:  Cesar Muñoz-Fontela; Dolores González; Laura Marcos-Villar; Michela Campagna; Pedro Gallego; José González-Santamaría; Daniel Herranz; Wei Gu; Manuel Serrano; Stuart A Aaronson; Carmen Rivas
Journal:  Cell Cycle       Date:  2011-11-01       Impact factor: 4.534

7.  Resistance to rabies virus infection conferred by the PMLIV isoform.

Authors:  Danielle Blondel; Sabrina Kheddache; Xavier Lahaye; Laurent Dianoux; Mounira K Chelbi-Alix
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

Review 8.  PML nuclear bodies.

Authors:  Valérie Lallemand-Breitenbach; Hugues de Thé
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

9.  SIRT1 stabilizes PML promoting its sumoylation.

Authors:  M Campagna; D Herranz; M A Garcia; L Marcos-Villar; J González-Santamaría; P Gallego; S Gutierrez; M Collado; M Serrano; M Esteban; C Rivas
Journal:  Cell Death Differ       Date:  2010-06-25       Impact factor: 15.828

10.  The SP100 component of ND10 enhances accumulation of PML and suppresses replication and the assembly of HSV replication compartments.

Authors:  Pei Xu; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.